Patents Assigned to Bausch & Lomb Incorporated
-
Patent number: 11066530Abstract: A method for preparing an ophthalmic device containing an ultraviolet (UV) blocker is disclosed. The method involves (a) soaking an ophthalmic device in one or more first solvent solutions to swell the ophthalmic device; (b) soaking the swelled ophthalmic device in one or more second solvents solutions comprising a UV blocker to de-swell the ophthalmic device and entrap the UV blocker in the ophthalmic device, wherein the UV blocker is a benzotriazole and (c) sterilizing the de-swelled ophthalmic device.Type: GrantFiled: March 22, 2019Date of Patent: July 20, 2021Assignee: Bausch & Lomb IncorporatedInventors: James Anthony DiBella, Jr., George L. Grobe, III, Alok Kumar Awasthi
-
Patent number: 11058691Abstract: This invention provides a method of lowering intraocular pressure in a patient having normal tension glaucoma, comprising contacting an eye of a subject having normal tension glaucoma with a pharmaceutical composition comprising an effective amount of Nitric Oxide releasing prostaglandin derivatives of formula (I).Type: GrantFiled: November 7, 2017Date of Patent: July 13, 2021Assignees: Nicox S.A., Bausch & Lomb IncorporatedInventors: Jason Lamar Vittitow, Megan Elizabeth Cavet
-
Patent number: 11022722Abstract: A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more organosilicon-containing block copolymers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group. The water extractable ophthalmic device has an equilibrium water content of at least about 50 wt. %, a contact angle of less than about 50°, and an oxygen permeability of at least about 60 Barrers.Type: GrantFiled: May 17, 2019Date of Patent: June 1, 2021Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nuñez, Katie L. Poetz, Lynn Coullard, Alok Kumar Awasthi, Analuz Mark, Joseph W. Hoff, Andrew J. Hoteling
-
Patent number: 10987246Abstract: An ophthalmic surgical device includes a housing having a distal end and a proximal end. A cannula is attached to the housing distal end and has a distal tip with at least one port in communication with a lumen extending through the cannula and in communication with an aspiration path in the housing. A vibration source is held within the housing for vibrating the distal tip of the cannula for assisting in vitreous and other tissue removal from a patient's eye. The vibration source creates a peak velocity of the distal tip equal to or less than a potential maximum flow velocity of water through the at least one port for a pressure differential between an intraocular pressure of the eye and a pressure within the cannula lumen that is less than the intraocular pressure.Type: GrantFiled: October 14, 2016Date of Patent: April 27, 2021Assignee: Bausch & Lomb IncorporatedInventors: Brian D. McCary, Toh Seng Goh, James Taylor Perkins
-
Patent number: 10932948Abstract: A phacoemulsification needle includes a hub for connection to an ultrasonic handpiece. An elongated shaft is formed with the hub and extends from the hub. A distal end of the shaft breaks-up tissue when the distal end is caused to be vibrated by the handpiece. At least a distal portion of the shaft is formed of a material that has properties providing advantages compared to a metal needle. Example properties include a substantially lower density, a substantially higher electrical resistivity, a substantially lower thermal conductivity, a substantially lower mechanical lateral stiffness, a substantially higher efficiency of converting electrical energy powering the handpiece into motion of the distal end, a substantially lower acoustical impedance, a substantially higher Poisson's ratio, and a substantially higher mechanical gain.Type: GrantFiled: April 20, 2015Date of Patent: March 2, 2021Assignee: Bausch & Lomb IncorporatedInventors: Ala Moradian, Brian D. McCary, Toh Seng Goh, Matthew J. Fitzgerald
-
Patent number: 10870731Abstract: A method is disclosed which involves the steps of (a) reacting a polysiloxane prepolymer having reactive functional end groups with a non-free radical polymerizable reactive end-capping agent; and (b) reacting the reaction product of step (a) with a free radical polymerizable reactive end-capping agent.Type: GrantFiled: January 14, 2019Date of Patent: December 22, 2020Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nuñez, Katie L. Poetz, Andrew J. Hoteling, Joseph W. Hoff, Lynn Coullard, Analuz Mark, Keyla M. Cubi, Joseph A. McGee
-
Patent number: 10816698Abstract: An ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more first non-silicone-containing hydrophilic monomers; (b) one or more hydrophobic monomers; and (c) a crosslinking agent mixture comprising (i) one or more di-, tri- or tetra(meth)acrylate-containing crosslinking agents and (ii) one or more di-, tri- or tetracarbamate-containing crosslinking agents, wherein the ophthalmic device has an equilibrium water content of at least about 65 weight percent.Type: GrantFiled: August 10, 2018Date of Patent: October 27, 2020Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nuñez, Katie L. Poetz, Joseph W. Hoff, Judith Chapman Morgan
-
Patent number: 10736841Abstract: Novel compositions including bepotastine besilate and a corticosteroid are provided, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV.Type: GrantFiled: May 2, 2012Date of Patent: August 11, 2020Assignee: BAUSCH & LOMB INCORPORATEDInventors: Angel Padilla, George Baklayan
-
Patent number: 10722346Abstract: A shuttle, vial and injector are provided for storing and presenting an IOL to a patient. The shuttle includes operably engaged shuttle plates having a set of confronting surfaces that flex about a flexure interface between a storage configuration, with at least an optic of an IOL in a nominal state and a loading configuration, with at least an optic of an IOL in a deformed state. The vial engages the shuttle and maintains the shuttle in the storage configuration. The injector receives the shuttle from the vial and includes surfaces for flexing the portions of the shuttle plates to the loading configuration upon engagement with the injector, wherein the shuttle plates impart a predetermined curvature to at least a portion of the IOL.Type: GrantFiled: September 19, 2017Date of Patent: July 28, 2020Assignee: Bausch & Lomb IncorporatedInventors: Moises A. Valle, Madhu S. Ayyagari, Sr., Sushant P. Muchhala, Sanjeev Bakshi
-
Patent number: 10716706Abstract: A system and method are provided for fragmenting a crystalline lens, to facilitate its removal from the lens bag during an ophthalmic laser surgery. First, a predetermined pattern is used to make Laser Induced Optical Breakdown (LIOB) cuts that section the lens into asymmetrical, operational segments. At least one operational segment is then selected and softened with a plurality of compact LIOB cuts. Once softened, the selected segment is aspirated. The remaining operational segments are then subsequently removed. During a procedure, an imaging unit can monitor movements of the lens bag to ensure proper placement of the LIOB cuts on the lens.Type: GrantFiled: March 30, 2012Date of Patent: July 21, 2020Assignees: BAUSCH & LOMB INCORPORATED, TECHNOLAS PERFECT VISION GMBHInventors: Frieder Loesel, Jochen Kandulla, Friedrich Moritz, Gwillem Mosedale, Holger Schlueter, Roland Toennies, Gerhard Youssefi, David Haydn Mordaunt
-
Patent number: 10668676Abstract: An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (“RAFT”) agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.Type: GrantFiled: August 10, 2018Date of Patent: June 2, 2020Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nuñez, Lynn Coullard, Daniel J. Hook, Robert B. Steffen, Daniel M. Ammon, Jennifer M. Hunt, Analuz Mark
-
Patent number: 10598955Abstract: The disclosure generally describes methods, systems and products relating to the development and manufacture of scleral contact lenses. A number of dimensions for the scleral lens is generated based on control points and attendant curvature parameters. Any change to one or more of the curve parameters imparts an improved anterior and posterior surface of the scleral lens and associated thickness, while undesired modifications to control points and other curve parameters remain static inasmuch as the sagittal depth component is an input parameter of the present disclosure.Type: GrantFiled: May 26, 2016Date of Patent: March 24, 2020Assignee: Bausch & Lomb IncorporatedInventor: Charles H. Creighton
-
Patent number: 10596107Abstract: A suspension includes an ophthalmic active ingredient suspended in a formulation vehicle including a suspending agent and a non-ionic cellulose derivative. The ophthalmic active agent is present as particles having Dv90<5 ?m and Dv50<1 ?m. The suspension may be administered to a patient for treating an ophthalmic inflammatory condition.Type: GrantFiled: January 26, 2016Date of Patent: March 24, 2020Assignee: Bausch & Lomb IncorporatedInventors: Mohannad Shawer, Eric Phillips, Martin J. Coffey
-
Patent number: 10555832Abstract: An intraocular lens (IOL) injector assembly comprising an injector body having a shuttle reception opening defined at least in part by a first sidewall and a second sidewall, and a shuttle comprising a first wing including a first portion of a shuttle lumen wall and a second wing including a second portion of a shuttle lumen wall. The first wing and the second wing are coupled together by a hinge. When in a closed state, the first portion of the shuttle lumen wall and the second portion of the shuttle lumen wall define at least a portion of an operative shuttle lumen. The shuttle and sidewalls are configured such that the first wing and the second wing interfere with the first sidewall and the second sidewall, respectively, as the shuttle passes through the shuttle reception opening, such that the closed state of the shuttle is attained.Type: GrantFiled: August 18, 2017Date of Patent: February 11, 2020Assignee: Bausch & Lomb IncorporatedInventors: Graham W. Biddle, Jon P. Cullen, Emin Engin, Bryan M. Reed, William J. Seyboth, Moises A. Valle, Christopher E. Wagner
-
Patent number: 10434011Abstract: A system and method are provided for removing a natural lens and inserting an Intraocular Lens (IOL) into the lens capsule of an eye. Specifically, this is accomplished by inserting the IOL through an opening on the posterior capsule that is created using a focused laser beam. The system includes a laser unit, a detector for creating images of the interior of the eye, and a computer that controls the cooperative functions of the detector and the laser unit. Based on images of the posterior capsule provided by the detector, the computer is used to control movements of the focal point through tissue of the posterior capsule to perform Laser Induced Optical Breakdown (LIOB) on posterior capsule tissue. The result is a laser capsulotomy that creates an opening through the posterior capsule allowing the natural lens to be removed and the IOL to be implanted.Type: GrantFiled: January 18, 2018Date of Patent: October 8, 2019Assignees: Bausch & Lomb Incorporated, Technolas Perfect Vision GMBHInventors: David Haydn Mordaunt, Frieder Loesel, Gwillem Mosedale
-
Patent number: 10434012Abstract: A system and method are provided for removing a natural lens and inserting an Intraocular Lens (IOL) into the lens capsule of an eye. Specifically, this is accomplished by inserting the IOL through an opening on the posterior capsule that is created using a focused laser beam. The system includes a laser unit, a detector for creating images of the interior of the eye, and a computer that controls the cooperative functions of the detector and the laser unit. Based on images of the posterior capsule provided by the detector, the computer is used to control movements of the focal point through tissue of the posterior capsule to perform Laser Induced Optical Breakdown (LIOB) on posterior capsule tissue. The result is a laser capsulotomy that creates an opening through the posterior capsule allowing the natural lens to be removed and the IOL to be implanted.Type: GrantFiled: January 18, 2018Date of Patent: October 8, 2019Assignees: Bausch & Lomb Incorporated, Technolas Perfect Vision GMBHInventors: David Haydn Mordaunt, Frieder Loesel, Gwillem Mosedale
-
Patent number: 10274751Abstract: A contact lens with a toric optical zone has its anterior and posterior optical zone surfaces tilted with respect to one another to forming prism in the optical zone. Thickness profiles of the peripheral region are independent of the tilt angle between the anterior and posterior optical zone surfaces.Type: GrantFiled: June 30, 2017Date of Patent: April 30, 2019Assignee: Bausch & Lomb IncorporatedInventors: Kristen R. Hovinga, Anita M. Graney
-
Patent number: 10130733Abstract: The invention is directed to a method of cleaning and disinfecting a contact lens. The method includes instructing a consumer to disinfect their contact lens comprising the following steps: remove a contact from an eye and position the lens in a lens assembly that includes a cap member; add a disinfection solution to the lens case such that the lens is submerged in the solution upon closure of the lens case with the cap member. The disinfection solution will comprise 0.5 wt. % to 6 wt. % hydrogen peroxide or a chemical precursor of hydrogen peroxide, and a P-metal modulating compound. The presence of the P-metal modulating compound in the disinfection solution decreases the neutralization rate of the hydrogen peroxide. The disinfection system exhibits a pseudo first-order, half-life of hydrogen peroxide from 12 minutes to 30 minutes over an initial sixty minutes of neutralization following exposure of the disinfection solution to a catalyst comprising a P-metal.Type: GrantFiled: March 15, 2013Date of Patent: November 20, 2018Assignee: Bausch & Lomb IncorporatedInventors: Kimberly Anne Millard, Erning Xia, Suzanne F. Groemminger, Jenilee Kilbury
-
Patent number: 10133089Abstract: A system and a method of cast molding toric contact lenses permits aligning first and second mold sections at multiple rotational positions. Each mold section includes a set of alignment features that engage with complementary alignment features on the other mold section.Type: GrantFiled: April 27, 2016Date of Patent: November 20, 2018Assignee: Bausch & Lomb IncorporatedInventors: Michael Henry Dobner, Craig A. Barrile-Josephson
-
Patent number: 10076445Abstract: A system and method are provided for removing a natural lens and inserting an Intraocular Lens (IOL) into the lens capsule of an eye. Specifically, this is accomplished by inserting the IOL through an opening on the posterior capsule that is created using a focused laser beam. The system includes a laser unit, a detector for creating images of the interior of the eye, and a computer that controls the cooperative functions of the detector and the laser unit. Based on images of the posterior capsule provided by the detector, the computer is used to control movements of the focal point through tissue of the posterior capsule to perform Laser Induced Optical Breakdown (LIOB) on posterior capsule tissue. The result is a laser capsulotomy that creates an opening through the posterior capsule allowing the natural lens to be removed and the IOL to be implanted.Type: GrantFiled: March 14, 2013Date of Patent: September 18, 2018Assignees: BAUSCH & LOMB INCORPORATED, TECHNOLAS PERFECT VISION GMBHInventors: David Haydn Mordaunt, Frieder Loesel, Gwillem Mosedale